Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (855)	5/5/2007 9:23:55 AM
From: Robohogs	Respond to of 897

All they need to say next is that it works for obesity too! Jon

To: sim1 who wrote (855)	7/8/2008 6:35:22 PM
From: tuck	Read Replies (1) \| Respond to of 897

Medivation posts cloudy results in Huntington's trial. It had "inadvertently" misled investors as to one of the primary endpoints. The company listed the UHDRS scale as primary endpoint since the beginning, about two years ago. Oops, that's actually a secondary endpoint now. How convenient, as dimebon whiffed on that endpoint: siliconinvestor.com MDVN stock has been mildly volatile the last few days. Still, it's well down from the $20 or so range that I last shorted it. I no longer have the position. But might restart it via a bear spread or something like that. Cheers, Tuck